|
|
Article: DUPONT MERCK GRANTED SUMMARY JUDGMENT IN BRAND NAME PRESCRIPTION DRUG ANTITRUST SUIT
- Article from:
- PR Newswire
- Article date:
- February 13, 1996
|
Copyright informationCOPYRIGHT 1996 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
WILMINGTON, Del., Feb. 13 /PRNewswire/ -- The DuPont Merck Pharmaceutical Company's motion for summary judgment was granted in the Brand Name Prescription Drug Antitrust Litigation currently pending in Federal District Court in Chicago. The court determined that based on the company's single price policy there was not enough material fact that would allow the plaintiff to sustain claims of conspiracy.
"Our pricing policy has always been one of single price, and we stood by our principles to prove we offer consistent pricing to our customers," said Kurt M. Landgraf, President and Chief Executive Officer, DuPont Merck.
Beginning in 1994, lawyers representing more than 40,000 ...